Gene: Kcnj1 (potassium inwardly-rectifying channel, subfamily J, member 1)
Mus musculus |
| Symbol: |
Kcnj1
|
| Name: |
potassium inwardly-rectifying channel, subfamily J, member 1
|
| Description: |
ENCODES a protein that exhibits ATP-activated inward rectifier potassium channel activity (ortholog); inward rectifier potassium channel activity (ortholog); peptide binding (ortholog); INVOLVED IN cardiovascular system development; kidney development; post-embryonic development; PARTICIPATES IN aldosterone signaling pathway; ASSOCIATED WITH abnormal urine homeostasis; acidosis; decreased renal glomerular filtration rate; ASSOCIATED WITH Bartter Syndrome (ortholog); Bartter syndrome, antenatal , type 2 (ortholog); FOUND IN plasma membrane (ortholog); INTERACTS WITH 2,3,7,8-tetrachlorodibenzodioxine; indomethacin; sodium chloride |
| Type: |
protein-coding
|
| RefSeq Status: |
VALIDATED
|
| Also known as: |
ATP-regulated potassium channel ROM-K; ATP-sensitive inward rectifier potassium channel 1; inward rectifier K(+) channel Kir1.1; inwardly rectifying potassium channel ROMK-2; Kir1.1; potassium channel, inwardly rectifying subfamily J member 1; ROMK; Romk2
|
| Orthologs: |
Homo sapiens : KCNJ1
(potassium inwardly-rectifying channel, subfamily J, member 1)
HGNC
Rattus norvegicus : Kcnj1
(potassium inwardly-rectifying channel, subfamily J, member 1)
|
| Latest Assembly: |
Mouse Genome Assembly Build 37
|
| Position: |
| Map | Chr | Position | Strand | Source |
|---|
Mouse Genome Assembly GRCm38 | 9 | 32,372,418 - 32,399,197 | + | NCBI | Mouse cM Map | 9 | | + | NCBI | Mouse Celera Assembly | 9 | 29,635,143 - 29,662,007 | + | NCBI | Mouse Genome Assembly Build 37 | 9 | 32,180,003 - 32,206,782 | + | NCBI | Mouse Genome Assembly Build 36.1 | 9 | 32,201,570 - 32,206,782 | + | NCBI | Mouse Cytogenetic Map | 9 | A4 | | NCBI |
|
| Model |
|
 Disease Annotations |
 Gene-Chemical Interaction Annotations
| (S)-amphetamine | decreases activity | ISO | RGD:2957 | 6480464 | Dextroamphetamine results in decreased activity of KCNJ1 protein | CTD | PMID:18571730 | | 2,3,7,8-tetrachlorodibenzodioxine | multiple interactions | EXP | | 6480464 | Indomethacin inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of KCNJ1 mRNA] | CTD | PMID:19782052 | | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | EXP | | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of KCNJ1 mRNA | CTD | PMID:19782052 PMID:22430074 | | 2,3,7,8-tetrachlorodibenzodioxine | multiple interactions | EXP | | 6480464 | PTGES protein affects the reaction [Tetrachlorodibenzodioxin results in decreased expression of KCNJ1 mRNA] | CTD | PMID:22430074 | | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | EXP | | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of KCNJ1 mRNA | CTD | PMID:19782052 | | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | EXP | | 6480464 | Tetrachlorodibenzodioxin affects the expression of KCNJ1 mRNA | CTD | PMID:18606429 | | ammonium chloride | affects expression | ISO | RGD:2957 | 6480464 | Ammonium Chloride affects the expression of KCNJ1 mRNA | CTD | PMID:16483693 | | benzo[a]pyrene | decreases expression | ISO | RGD:732016 | 6480464 | Benzo(a)pyrene results in decreased expression of KCNJ1 mRNA | CTD | PMID:20064835 | | calcitriol | increases expression | ISO | RGD:732016 | 6480464 | Calcitriol results in increased expression of KCNJ1 mRNA | CTD | PMID:21592394 | | calcitriol | multiple interactions | ISO | RGD:732016 | 6480464 | [Testosterone co-treated with Calcitriol] results in increased expression of KCNJ1 mRNA | CTD | PMID:21592394 | | geneticin | increases expression | ISO | RGD:732016 | 6480464 | antibiotic G 418 results in increased expression of KCNJ1 protein mutant form | CTD | PMID:12911542 | | indomethacin | multiple interactions | EXP | | 6480464 | Indomethacin inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of KCNJ1 mRNA] | CTD | PMID:19782052 | | ochratoxin A | decreases expression | ISO | RGD:732016 | 6480464 | ochratoxin A results in decreased expression of KCNJ1 mRNA | CTD | PMID:22124623 | | ochratoxin A | decreases expression | ISO | RGD:2957 | 6480464 | ochratoxin A results in decreased expression of KCNJ1 mRNA | CTD | PMID:22124623 | | potassium atom | decreases transport | ISO | RGD:732016 | 6480464 | KCNJ1 protein mutant form results in decreased transport of Potassium | CTD | PMID:12911542 | | potassium atom | increases transport | ISO | RGD:732016 | 6480464 | KCNJ1 protein results in increased transport of Potassium | CTD | PMID:12911542 | | sodium chloride | decreases expression | EXP | | 6480464 | Sodium Chloride results in decreased expression of KCNJ1 mRNA | CTD | PMID:19782052 | | tamoxifen | increases expression | ISO | RGD:732016 | 6480464 | Tamoxifen results in increased expression of KCNJ1 mRNA | CTD | PMID:19155303 | | testosterone | increases expression | ISO | RGD:732016 | 6480464 | Testosterone results in increased expression of KCNJ1 mRNA | CTD | PMID:21592394 | | testosterone | multiple interactions | ISO | RGD:732016 | 6480464 | [Testosterone co-treated with Calcitriol] results in increased expression of KCNJ1 mRNA | CTD | PMID:21592394 | | tetrachloromethane | decreases expression | ISO | RGD:2957 | 6480464 | Carbon Tetrachloride results in decreased expression of KCNJ1 mRNA | CTD | PMID:16644059 | | tetrachloromethane | affects expression | ISO | RGD:2957 | 6480464 | Carbon Tetrachloride affects the expression of KCNJ1 mRNA | CTD | PMID:17805973 | | vancomycin | increases expression | EXP | | 6480464 | Vancomycin results in increased expression of KCNJ1 mRNA | CTD | PMID:18930951 | |
Biological Process
| cardiovascular system development | | IMP | MGI:MGI:2388372 | 2290270 | MGI:MGI:2387900|PMID:12122007 | MGI | MGI:MGI:2387900 PMID:12122007 |
| ion transmembrane transport | | IEA | UniProtKB-KW:KW-0407 | 2290270 | MGI:MGI:1354194 | GOC | MGI:MGI:1354194 |
| ion transport | | IEA | UniProtKB-KW:KW-0406 | 2290270 | MGI:MGI:1354194 | UniProtKB | MGI:MGI:1354194 |
| kidney development | | IMP | MGI:MGI:2388372 | 2290270 | MGI:MGI:2387900|PMID:12122007 | MGI | MGI:MGI:2387900 PMID:12122007 |
| post-embryonic development | | IMP | MGI:MGI:2388372 | 2290270 | MGI:MGI:2387900|PMID:12122007 | MGI | MGI:MGI:2387900 PMID:12122007 |
| potassium ion transport | | ISO | UniProtKB:P35560 | 2290270 | MGI:MGI:4417868 | RGD | MGI:MGI:4417868 |
| regulation of G-protein activated inward rectifier potassium channel activity | | IMP | MGI:MGI:2388372 | 2290270 | MGI:MGI:2387899|PMID:12130653 | MGI | MGI:MGI:2387899 PMID:12130653 |
| regulation of ion transmembrane transport | | IEA | UniProtKB-KW:KW-0851 | 2290270 | MGI:MGI:1354194 | UniProtKB | MGI:MGI:1354194 |
| renal sodium ion absorption | | IMP | MGI:MGI:2388372 | 2290270 | MGI:MGI:2387900|PMID:12122007 | MGI | MGI:MGI:2387900 PMID:12122007 |
| tissue homeostasis | | IMP | MGI:MGI:2388372 | 2290270 | MGI:MGI:2387900|PMID:12122007 | MGI | MGI:MGI:2387900 PMID:12122007 |
| transport | | IEA | UniProtKB-KW:KW-0813 | 2290270 | MGI:MGI:1354194 | UniProtKB | MGI:MGI:1354194 |
Cellular Component
| integral to membrane | | IEA | UniProtKB-KW:KW-0812 | 2290270 | MGI:MGI:1354194 | UniProtKB | MGI:MGI:1354194 |
| integral to membrane | | IEA | InterPro:IPR016449 | 2290270 | MGI:MGI:2152098 | UniProtKB | MGI:MGI:2152098 |
| membrane | | IEA | UniProtKB-KW:KW-0472 | 2290270 | MGI:MGI:1354194 | UniProtKB | MGI:MGI:1354194 |
| membrane | | IEA | InterPro:IPR003268 | 2290270 | MGI:MGI:2152098 | UniProtKB | MGI:MGI:2152098 |
| plasma membrane | | ISO | UniProtKB:P35560 | 2290270 | MGI:MGI:4417868 | RGD | MGI:MGI:4417868 |
Molecular Function
| ATP binding | | IEA | UniProtKB-KW:KW-0067 | 2290270 | MGI:MGI:1354194 | UniProtKB | MGI:MGI:1354194 |
| ATP-activated inward rectifier potassium channel activity | | ISO | UniProtKB:P35560 | 2290270 | MGI:MGI:4417868 | RGD | MGI:MGI:4417868 |
| inward rectifier potassium channel activity | | ISO | UniProtKB:P35560 | 2290270 | MGI:MGI:4417868 | RGD | MGI:MGI:4417868 |
| ion channel activity | | IEA | UniProtKB-KW:KW-0407 | 2290270 | MGI:MGI:1354194 | UniProtKB | MGI:MGI:1354194 |
| nucleotide binding | | IEA | UniProtKB-KW:KW-0547 | 2290270 | MGI:MGI:1354194 | UniProtKB | MGI:MGI:1354194 |
| peptide binding | | ISO | UniProtKB:P35560 | 2290270 | MGI:MGI:4417868 | RGD | MGI:MGI:4417868 |
| potassium ion binding | | ISO | UniProtKB:P35560 | 2290270 | MGI:MGI:4417868 | RGD | MGI:MGI:4417868 |
| voltage-gated ion channel activity | | IEA | UniProtKB-KW:KW-0851 | 2290270 | MGI:MGI:1354194 | UniProtKB | MGI:MGI:1354194 |
| 4142455 | Elnv_m | epilepsy naive (mouse) | | | Not determined | | 9 | 31167847 | 37202659 | Mouse |
| 1357746 | Vtbt7_m | vertebral trabecular bone trait 7 (mouse) | | | Not determined | | 9 | 30636700 | 64636806 | Mouse |
| 4141260 | Actre6_m | activity response to ethanol 6 (mouse) | | | Not determined | | 9 | 30439809 | 64439925 | Mouse |
| 1558949 | Igan3_m | IgA nephropathy 3 (mouse) | | | Not determined | | 9 | 30310983 | 40462701 | Mouse |
| 1301365 | Ap5q_m | alcohol preference 5 QTL (mouse) | | | Not determined | | 9 | 29949949 | 63950062 | Mouse |
| 1558993 | Tdmq1_m | type 2 diabetes modifying QTL 1 (mouse) | | | Not determined | | 9 | 29041438 | 63041650 | Mouse |
| 1300932 | Hdlq17_m | HDL QTL 17 (mouse) | | | Not determined | | 9 | 26693207 | 60693338 | Mouse |
| 1301000 | Obq5_m | obesity QTL 5 (mouse) | | | Not determined | | 9 | 24695932 | 58696113 | Mouse |
| 1301334 | Cocia10_m | cocaine induced activation 10 (mouse) | | | Not determined | | 9 | 24695932 | 58696113 | Mouse |
| 1301501 | Lmr2_m | leishmaniasis resistance 2 (mouse) | | | Not determined | | 9 | 24362343 | 58362480 | Mouse |
| 4141166 | Appd1_m | APP associated premature death 1 (mouse) | | | Not determined | | 9 | 23462577 | 57462701 | Mouse |
| 1357900 | Alaa2_m | alopecia areata 2 (mouse) | | | Not determined | | 9 | 23315883 | 57315980 | Mouse |
| 1301631 | Orgwq7_m | organ weight QTL 7 (mouse) | | | Not determined | | 9 | 20202486 | 54202659 | Mouse |
| 4142352 | Lmr17_m | leishmaniasis resistance 17 (mouse) | | | Not determined | | 9 | 20202486 | 54202659 | Mouse |
| 1301883 | Skull12_m | skull morphology 12 (mouse) | | | Not determined | | 9 | 20202486 | 54202659 | Mouse |
| 4141507 | Brml5_m | bone response to mechanical loading 5 (mouse) | | | Not determined | | 9 | 20202486 | 54202659 | Mouse |
| 1302015 | C10bw2_m | castaneus 10 week body weight 2 (mouse) | | | Not determined | | 9 | 20202486 | 54202659 | Mouse |
| 1301045 | Sluc10_m | susceptibility to lung cancer 10 (mouse) | | | Not determined | | 9 | 20202486 | 54202659 | Mouse |
| 1301439 | Morph2_m | morphine antinociception 2 (mouse) | | | Not determined | | 9 | 20049651 | 54049781 | Mouse |
| 1301007 | Pid2_m | prion incubation determinant 2 (mouse) | | | Not determined | | 9 | 20049651 | 54049781 | Mouse |
| 1300643 | Pvcan2_m | protection against vaginal candidiasis 2 (mouse) | | | Not determined | | 9 | 19839695 | 53839814 | Mouse |
| 1357465 | Vtbt6_m | vertebral trabecular bone trait 6 (mouse) | | | Not determined | | 9 | 16875129 | 50875232 | Mouse |
| 4141447 | Cfmq2_m | cystic fibrosis modifier QTL 2 (mouse) | | | Not determined | | 9 | 15308040 | 49308179 | Mouse |
| 1301421 | Lgth4_m | body length 4 (mouse) | | | Not determined | | 9 | 15308040 | 49308179 | Mouse |
| 1300777 | Chol10_m | cholesterol 10 (mouse) | | | Not determined | | 9 | 15308040 | 49308179 | Mouse |
| 1357637 | Si5lq2_m | serum IGFBP-5 level QTL 2 (mouse) | | | Not determined | | 9 | 15308040 | 49308179 | Mouse |
| 4141591 | Cq4_m | cholesterol QTL 4 (mouse) | | | Not determined | | 9 | 15308040 | 49308179 | Mouse |
| 1301246 | Hpic5_m | haloperidol-induced catelepsy 5 (mouse) | | | Not determined | | 9 | 14167847 | 48167980 | Mouse |
| 1300532 | Tbs2_m | tuberculosis severity 2 (mouse) | | | Not determined | | 9 | 12266259 | 46266403 | Mouse |